SARS-CoV-2 infections may be 10 times higher than reported cases, according to new data from a Centers for Disease Control and Prevention partnership with commercial laboratories to test de-identified clinical blood specimens for antibodies in Connecticut, South Florida, the New York City area, Missouri, Utah and western Washington state.

The seroprevalence survey includes people who had blood specimens tested for SARS-CoV-2 antibodies for reasons unrelated to COVID-19, such as for a routine or sick visit. CDC is working with state and local health departments to publish additional results from California, Louisiana, Minnesota, and Pennsylvania.

The survey aims to test about 1,800 samples from each of the 10 areas every 3 to 4 weeks to track changes in the percentage of people tested who have antibodies against SARS-CoV-2 in each area.

Related News Articles

Headline
The Centers for Disease Control and Prevention yesterday recommended children age 5-11 receive a booster dose five months after completing the Pfizer COVID-19…
Headline
Learn how Loyola University Health System’s pop-up COVID-19 testing laboratory broadened collaboration between clinicians and hospital leadership, improved…
Headline
The Biden Administration plans to continue the COVID-19 public health emergency beyond July 15, administration officials told CNN this week. The…
Headline
U.S. residents can order online eight more free at-home tests for COVID-19, the White House announced yesterday. People who have difficulty accessing the…
Headline
The Food and Drug Administration today authorized a single Pfizer COVID-19 booster dose for children aged 5-11 who completed the Pfizer vaccine primary series…
Headline
A recent op-ed in the online publication STAT contains “blatant factual inaccuracies” and omits critical information about hospital and health systems’…